<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Technical Analysis - Imugene (IMU.AX) Stock Analysis</title>
    <link rel="stylesheet" href="css/style.css">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0-beta3/css/all.min.css">
    <meta name="robots" content="noindex, nofollow">
</head>
<body>
    <div class="sidebar">
        <div class="sidebar-title">
            Imugene Analysis
        </div>
        <ul class="sidebar-nav">
            <li><a href="index.html"><i class="fas fa-home"></i> Overview</a></li>
            <li><a href="financial_analysis.html"><i class="fas fa-chart-line"></i> Financial Analysis</a></li>
            <li><a href="clinical_trials.html"><i class="fas fa-flask"></i> Clinical Trials</a></li>
            <li><a href="technical_analysis.html" class="active"><i class="fas fa-chart-bar"></i> Technical Analysis</a></li>
            <li><a href="short_selling_analysis.html"><i class="fas fa-arrow-down"></i> Short Selling</a></li>
            <li><a href="market_position.html"><i class="fas fa-building"></i> Competitor Analysis</a></li>
            <li><a href="investment_recommendations.html"><i class="fas fa-lightbulb"></i> Investment Thesis</a></li>
            <li><a href="options_trading.html"><i class="fas fa-exchange-alt"></i> Options Trading</a></li>
            <li><a href="csl_case_study.html"><i class="fas fa-microscope"></i> CSL Case Study</a></li>
            <li><a href="catalyst_calendar.html"><i class="fas fa-calendar-alt"></i> Catalyst Calendar</a></li>
        </ul>
    </div>

    <div class="main-content">
        <div class="page-header">
            <h1 class="page-title">Technical Analysis - Imugene (IMU.AX)</h1>
            <div class="header-actions">
                <button class="btn"><i class="fas fa-share-alt"></i> Share</button>
                <button class="btn"><i class="fas fa-file-export"></i> Export</button>
                <button class="btn btn-primary"><i class="fas fa-calendar-week"></i> This week</button>
            </div>
        </div>

        <section class="section">
            <h2 class="section-title">Price Chart with Moving Averages</h2>
            <div class="card">
                <h3 class="card-title">Imugene (IMU.AX) Price with Moving Averages</h3>
                <p>The chart below shows Imugene's share price with 20-day, 50-day, and 200-day simple moving averages (SMAs), along with key support and resistance levels.</p>
                <img src="img/price_with_ma.png" alt="Price with Moving Averages">
                
                <h4 class="card-subtitle">Technical Indicators</h4>
                <ul>
                    <li><strong>Current Price:</strong> $0.03 AUD</li>
                    <li><strong>20-Day SMA:</strong> $0.035 AUD (Price below)</li>
                    <li><strong>50-Day SMA:</strong> $0.038 AUD (Price below)</li>
                    <li><strong>200-Day SMA:</strong> $0.045 AUD (Price below)</li>
                    <li><strong>Support Level:</strong> $0.030 AUD</li>
                    <li><strong>Resistance Level:</strong> $0.047 AUD</li>
                </ul>
                
                <h4 class="card-subtitle">Technical Analysis Summary</h4>
                <p>Imugene's share price is currently trading below all major moving averages, indicating a bearish trend in the short to medium term. The price has been in a downtrend since early 2024, with a series of lower highs and lower lows.</p>
                <p>The stock is currently testing a key support level at $0.030. A break below this level could lead to further downside, while a bounce from this level could indicate a potential reversal.</p>
            </div>
        </section>

        <section class="section">
            <h2 class="section-title">Volume Analysis</h2>
            <div class="card">
                <h3 class="card-title">Trading Volume Patterns</h3>
                <p>Recent trading volume has been below average, indicating reduced investor interest. However, there have been occasional volume spikes coinciding with company announcements and clinical trial updates.</p>
                
                <h4 class="card-subtitle">Volume Indicators</h4>
                <ul>
                    <li><strong>Average Daily Volume (3 months):</strong> 5.2 million shares</li>
                    <li><strong>Average Daily Volume (10 days):</strong> 3.8 million shares</li>
                    <li><strong>Volume Trend:</strong> Declining</li>
                </ul>
                
                <p>The declining volume trend suggests diminishing market interest, which is typical for stocks in a prolonged downtrend. However, this could also indicate a potential bottoming process if accompanied by price stabilization.</p>
            </div>
        </section>

        <section class="section">
            <h2 class="section-title">Relative Strength Analysis</h2>
            <div class="card">
                <h3 class="card-title">Relative Performance</h3>
                <p>Imugene has underperformed both the broader ASX 200 index and the ASX Healthcare sector over the past 12 months.</p>
                
                <h4 class="card-subtitle">Relative Performance Metrics</h4>
                <ul>
                    <li><strong>vs. ASX 200 (12 months):</strong> -65%</li>
                    <li><strong>vs. ASX Healthcare Index (12 months):</strong> -58%</li>
                    <li><strong>vs. ASX Biotech Peers (12 months):</strong> -42%</li>
                </ul>
                
                <p>This significant underperformance reflects both sector-specific challenges and company-specific factors, including clinical trial timelines and cash burn concerns.</p>
            </div>
        </section>

        <section class="section">
            <h2 class="section-title">Share Price Scenarios</h2>
            <div class="card">
                <h3 class="card-title">Potential Share Price Targets</h3>
                <p>Based on technical analysis and potential catalysts, the following price scenarios have been identified:</p>
                
                <img src="img/share_price_scenarios.png" alt="Share Price Scenarios">
                
                <h4 class="card-subtitle">Technical Price Targets</h4>
                <ul>
                    <li><strong>Bearish Case:</strong> $0.020 (33% downside) - Break below support with no positive catalysts</li>
                    <li><strong>Base Case:</strong> $0.045-0.050 (50-67% upside) - Successful trial results and improved market sentiment</li>
                    <li><strong>Bullish Case:</strong> $0.080-0.100 (167-233% upside) - Multiple positive catalysts and partnership announcements</li>
                </ul>
            </div>
        </section>

        <section class="section">
            <h2 class="section-title">Technical Trading Recommendations</h2>
            <div class="card">
                <h3 class="card-title">Trading Strategy Based on Technical Analysis</h3>
                
                <h4 class="card-subtitle">Short-Term Traders (1-3 months)</h4>
                <p><strong>Recommendation:</strong> Neutral with bearish bias</p>
                <p>Current technical indicators suggest caution for short-term traders. The stock is in a downtrend below all major moving averages, but is testing a key support level. Consider waiting for confirmation of a bounce from support before establishing new positions.</p>
                
                <h4 class="card-subtitle">Medium-Term Traders (3-12 months)</h4>
                <p><strong>Recommendation:</strong> Accumulate on weakness</p>
                <p>For medium-term traders with higher risk tolerance, the current price levels near multi-year lows may present accumulation opportunities. Consider establishing partial positions at current levels with plans to add on either confirmation of support or positive catalyst announcements.</p>
                
                <h4 class="card-subtitle">Key Technical Levels to Watch</h4>
                <ul>
                    <li><strong>Support:</strong> $0.030 (current), $0.025 (secondary)</li>
                    <li><strong>Resistance:</strong> $0.035 (20-day SMA), $0.047 (recent high)</li>
                    <li><strong>Volume Trigger:</strong> Daily volume exceeding 10 million shares could signal increased interest</li>
                </ul>
            </div>
        </section>

        <footer>
            <p>Imugene (IMU.AX) Investment Analysis - April 2025</p>
            <p><a href="https://github.com/Hodge2Franklin/Imugene" target="_blank">View on GitHub</a></p>
        </footer>
    </div>
</body>
</html>
